Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2021

01-06-2021 | Ampicillin | Research Article

Off-label antibiotic use among paediatric in-patients: a mixed-method prospective study at a tertiary hospital in southwestern Uganda

Authors: Bonniface Obura, Paul E. Alele, Celestino Obua

Published in: International Journal of Clinical Pharmacy | Issue 3/2021

Login to get access

Abstract

Background The off-label use of drugs to treat children is a global practice attributed to the traditional exclusion of children from clinical trials mainly due to practical and ethical reasons. Off-label drug use carries both benefits and risks, but data regarding this use pattern are scanty in sub-Saharan Africa. Objective To determine the incidence and predictors of off-label antibiotic use in children less than 5 years admitted at Mbarara Regional Referral Hospital (MRRH) in southwestern Uganda. Setting A prospective drug utilisation study was conducted among in-patients at the Paediatric Ward of MRRH from May to June 2019. Methods Clinical records and treatment notes of all children aged 0 to 59 months with at least one antibiotic prescription during the admission period were reviewed and included for data collection. Key informant interviews were conducted with physicians attending to patients in the Paediatric Ward. Main outcome measure Off-label use and potential predictors of off-label antibiotic use. Results Of 427 children admitted to the Paediatric Ward, 165 (38.6%) received 366 antibiotic prescriptions. However, 359 prescriptions belonging to 162 patients were analyzed. Off-label prescriptions occurred in 18.9% (95% CI: 14.9–23.0) of antibiotic prescriptions. Two categories of off-label prescriptions were found: off-label frequency of administration (n = 55, 80.9%), and off-label doses (n = 13, 19.1%). Ceftriaxone was the most common antibiotic prescribed at off-label doses, (n = 6, 8.8%) while ampicillin was the most common antibiotic prescribed with an off-label frequency of administration, (n = 39, 57.3%). Infants (1–23 months) received the majority (47.1%) of off-label antibiotic prescriptions; neonates (0–28 days) received 27.9%, and children (24–59 months) received 25% of the prescriptions. Controlling for sex and disease severity, age category remained significantly associated with off-label antibiotic use on multivariate analysis. Conclusion Off-label frequency of administration was the major category of off-label drug use, while off-label dose was the minor category. Age was a significant factor for off-label antibiotic prescription, with infants receiving the highest number of off-label prescriptions. Attending physicians identified several justifiable circumstances that warrant off-label antibiotic use and support emerging “well-founded” off-label uses of antibiotics in different paediatric age groups.
Appendix
Available only for authorised users
Literature
1.
go back to reference Golombek SG, van den Anker J, Rose K. Clinical trials in children. Int J Pharm Med. 2007;21:121–9.CrossRef Golombek SG, van den Anker J, Rose K. Clinical trials in children. Int J Pharm Med. 2007;21:121–9.CrossRef
2.
go back to reference Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79:357–69.CrossRef Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79:357–69.CrossRef
3.
go back to reference Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91:796–801.CrossRef Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91:796–801.CrossRef
4.
go back to reference Zingg W, Posfay-Barbe MK. Antibiotic use in children-off-label use. Curr Drug Targets. 2012;13:885–92.CrossRef Zingg W, Posfay-Barbe MK. Antibiotic use in children-off-label use. Curr Drug Targets. 2012;13:885–92.CrossRef
5.
go back to reference Joret-Descout P, Prot-Labarthe S, Brion F, Bataille J, Hartmann J-F, Bourdon O. Off-label and unlicensed utilisation of medicines in a French paediatric hospital. Int J Clin Pharm. 2015;37:1222–7.CrossRef Joret-Descout P, Prot-Labarthe S, Brion F, Bataille J, Hartmann J-F, Bourdon O. Off-label and unlicensed utilisation of medicines in a French paediatric hospital. Int J Clin Pharm. 2015;37:1222–7.CrossRef
6.
go back to reference Mukattash TL, Hayajneh WA, Ibrahim SM, Ayoub A, Ayoub N, Jarab AS, et al. Prevalence and nature of off-label antibiotic prescribing for children in a tertiary setting: a descriptive study from Jordan. Pharm Pract Granada. 2016;14:725.CrossRef Mukattash TL, Hayajneh WA, Ibrahim SM, Ayoub A, Ayoub N, Jarab AS, et al. Prevalence and nature of off-label antibiotic prescribing for children in a tertiary setting: a descriptive study from Jordan. Pharm Pract Granada. 2016;14:725.CrossRef
7.
go back to reference Uganda National Drug Authority. Guidelines on submission of documentation for marketing authorisation of a pharmaceutical product for human use. 2018. Uganda National Drug Authority. Guidelines on submission of documentation for marketing authorisation of a pharmaceutical product for human use. 2018.
8.
go back to reference Parliament of Uganda. National drug policy and authority act. Uganda. 1993. Parliament of Uganda. National drug policy and authority act. Uganda. 1993.
9.
go back to reference Neville KA, Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Paul IM, et al. Off-label use of drugs in children. Pediatrics. 2014;133:563–7.CrossRef Neville KA, Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Paul IM, et al. Off-label use of drugs in children. Pediatrics. 2014;133:563–7.CrossRef
10.
go back to reference Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358:1427–9.CrossRef Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358:1427–9.CrossRef
11.
go back to reference Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665.CrossRef Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665.CrossRef
12.
go back to reference Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27:1059–67.CrossRef Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27:1059–67.CrossRef
13.
go back to reference Kruger M, Makiwane MM, Ramoroka S, van Elsland SL, Lawrence K, Rosenkranz B. Off-label use in ambulatory paediatric clinics in a Central South African Hospital. J Trop Pediatr. 2018. Kruger M, Makiwane MM, Ramoroka S, van Elsland SL, Lawrence K, Rosenkranz B. Off-label use in ambulatory paediatric clinics in a Central South African Hospital. J Trop Pediatr. 2018.
14.
go back to reference Okechukwu RC, Aghom O. Prescription pattern of unlicensed and off-label medicines for children aged 0-5 years in a tertiary hospital and a primary health care centre in Nigeria. South Afr J Bioeth Law. 2009;2:2. Okechukwu RC, Aghom O. Prescription pattern of unlicensed and off-label medicines for children aged 0-5 years in a tertiary hospital and a primary health care centre in Nigeria. South Afr J Bioeth Law. 2009;2:2.
15.
go back to reference Oshikoya KA, Oreagba IA, Godman B, Fadare J, Orubu S, Massele A, et al. Off-label prescribing for children with chronic diseases in Nigeria; findings and implications. Expert Opin Drug Saf. 2017;16:981–8.CrossRef Oshikoya KA, Oreagba IA, Godman B, Fadare J, Orubu S, Massele A, et al. Off-label prescribing for children with chronic diseases in Nigeria; findings and implications. Expert Opin Drug Saf. 2017;16:981–8.CrossRef
16.
go back to reference Tefera YG, Gebresillassie BM, Mekuria AB, Abebe TB, Erku DA, Seid N, et al. Off‐label drug use in hospitalized children: a prospective observational study at Gondar University Referral Hospital, Northwestern Ethiopia. Pharmacol Res Perspect 5. 2017. Tefera YG, Gebresillassie BM, Mekuria AB, Abebe TB, Erku DA, Seid N, et al. Off‐label drug use in hospitalized children: a prospective observational study at Gondar University Referral Hospital, Northwestern Ethiopia. Pharmacol Res Perspect 5. 2017.
17.
go back to reference Hannsjorg WS, Anders R, Matthias S. Pediatric clinical pharmacology: handbook of experimental pharmacology. Berlin: Springer; 2011. XII. 384 p, ISBN: 978-3-642-20194-3. Hannsjorg WS, Anders R, Matthias S. Pediatric clinical pharmacology: handbook of experimental pharmacology. Berlin: Springer; 2011. XII. 384 p, ISBN: 978-3-642-20194-3.
18.
go back to reference World Health Organization. Hospital care for children: guidelines for management of common childhood illnesses. 2nd ed. Geneva: Switzerland; 2013. World Health Organization. Hospital care for children: guidelines for management of common childhood illnesses. 2nd ed. Geneva: Switzerland; 2013.
19.
go back to reference Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Int Med. 2012;172:781–8.CrossRef Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Int Med. 2012;172:781–8.CrossRef
20.
go back to reference Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11:32.CrossRef Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11:32.CrossRef
21.
go back to reference Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharm. 2009;48:143–57.CrossRef Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharm. 2009;48:143–57.CrossRef
22.
go back to reference Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59–82.CrossRef Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59–82.CrossRef
23.
go back to reference Galvin R. How many interviews are enough? Do qualitative interviews in building energy consumption research produce reliable knowledge? J Build Eng. 2015;1:2–12.CrossRef Galvin R. How many interviews are enough? Do qualitative interviews in building energy consumption research produce reliable knowledge? J Build Eng. 2015;1:2–12.CrossRef
24.
go back to reference Priest H, Roberts P, Woods L. An overview of three different approaches to the interpretation of qualitative data. Part 1: theoretical issues. Nurse Res. 2002;10:30–42.CrossRef Priest H, Roberts P, Woods L. An overview of three different approaches to the interpretation of qualitative data. Part 1: theoretical issues. Nurse Res. 2002;10:30–42.CrossRef
25.
go back to reference Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME. Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti infect Ther. 2012;10:1383–92.CrossRef Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME. Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti infect Ther. 2012;10:1383–92.CrossRef
26.
go back to reference Porta A, Esposito S, Menson E, Spyridis N, Tsolia M, Sharland M, et al. Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol. 2010;66:919–27.CrossRef Porta A, Esposito S, Menson E, Spyridis N, Tsolia M, Sharland M, et al. Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol. 2010;66:919–27.CrossRef
27.
go back to reference Santos DB, Clavenna A, Bonati M, Coelho HLL. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol. 2008;64:1111.CrossRef Santos DB, Clavenna A, Bonati M, Coelho HLL. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol. 2008;64:1111.CrossRef
28.
go back to reference W’t Jong G, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics. 2001;108:1089–93.CrossRef W’t Jong G, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics. 2001;108:1089–93.CrossRef
29.
go back to reference Gijsen R, Jochemsen H, van Dijk L, Caspers P. Frequency of ill-founded off-label prescribing in Dutch general practice. Pharmacoepidemiol Drug Saf. 2009;18:84–91.CrossRef Gijsen R, Jochemsen H, van Dijk L, Caspers P. Frequency of ill-founded off-label prescribing in Dutch general practice. Pharmacoepidemiol Drug Saf. 2009;18:84–91.CrossRef
Metadata
Title
Off-label antibiotic use among paediatric in-patients: a mixed-method prospective study at a tertiary hospital in southwestern Uganda
Authors
Bonniface Obura
Paul E. Alele
Celestino Obua
Publication date
01-06-2021
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 3/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01175-1

Other articles of this Issue 3/2021

International Journal of Clinical Pharmacy 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.